ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Purchased by Redmile Group LLC

Redmile Group LLC raised its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 18.2% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 4,326,509 shares of the company’s stock after acquiring an additional 667,245 shares during the period. ALX Oncology comprises about 1.8% of Redmile Group LLC’s investment portfolio, making the stock its 18th biggest position. Redmile Group LLC owned 0.08% of ALX Oncology worth $48,241,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. EntryPoint Capital LLC purchased a new position in ALX Oncology during the first quarter valued at approximately $32,000. CANADA LIFE ASSURANCE Co acquired a new stake in shares of ALX Oncology during the 1st quarter worth approximately $27,000. Vanguard Group Inc. increased its holdings in shares of ALX Oncology by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock valued at $17,466,000 after purchasing an additional 64,055 shares in the last quarter. Inspire Investing LLC acquired a new position in shares of ALX Oncology in the 1st quarter valued at $370,000. Finally, Swiss National Bank acquired a new stake in ALX Oncology during the first quarter valued at $493,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ALXO. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research report on Wednesday, May 29th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a report on Monday, June 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.67.

ALX Oncology Price Performance

ALXO traded down $0.20 during midday trading on Monday, hitting $5.85. 977,555 shares of the company traded hands, compared to its average volume of 632,018. The company has a market capitalization of $304.79 million, a price-to-earnings ratio of -1.57 and a beta of 1.06. The business has a 50 day simple moving average of $8.06 and a two-hundred day simple moving average of $12.09. The company has a current ratio of 5.21, a quick ratio of 5.21 and a debt-to-equity ratio of 0.06. ALX Oncology Holdings Inc. has a 52-week low of $3.94 and a 52-week high of $17.83.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.16. On average, equities analysts forecast that ALX Oncology Holdings Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling at ALX Oncology

In other ALX Oncology news, CFO Peter S. Garcia bought 12,000 shares of the company’s stock in a transaction dated Thursday, June 13th. The stock was acquired at an average price of $8.53 per share, with a total value of $102,360.00. Following the completion of the acquisition, the chief financial officer now directly owns 122,348 shares of the company’s stock, valued at $1,043,628.44. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CFO Peter S. Garcia bought 12,000 shares of the stock in a transaction dated Thursday, June 13th. The shares were acquired at an average cost of $8.53 per share, for a total transaction of $102,360.00. Following the acquisition, the chief financial officer now directly owns 122,348 shares in the company, valued at approximately $1,043,628.44. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jaume Pons sold 20,000 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.43, for a total value of $168,600.00. Following the completion of the sale, the insider now directly owns 604,205 shares of the company’s stock, valued at approximately $5,093,448.15. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 78,469 shares of company stock worth $873,346. Corporate insiders own 33.40% of the company’s stock.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.